Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
P68Time-course Of Human Rhinovirus Infection And Upper Respiratory Tract Symptoms During Copd Exacerbations
by
Kowlessar, B
, Donaldson, G C
, Brill, SE
, Singh, R
, Sapsford, R J
, Wedzicha, JA
, George, S N
, Allinson, J P
in
Human rhinovirus
2014
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
P68Time-course Of Human Rhinovirus Infection And Upper Respiratory Tract Symptoms During Copd Exacerbations
by
Kowlessar, B
, Donaldson, G C
, Brill, SE
, Singh, R
, Sapsford, R J
, Wedzicha, JA
, George, S N
, Allinson, J P
in
Human rhinovirus
2014
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
P68Time-course Of Human Rhinovirus Infection And Upper Respiratory Tract Symptoms During Copd Exacerbations
Journal Article
P68Time-course Of Human Rhinovirus Infection And Upper Respiratory Tract Symptoms During Copd Exacerbations
2014
Request Book From Autostore
and Choose the Collection Method
Overview
IntroductionHuman rhinoviruses (HRV) are the main aetiological agents of virus-associated COPD exacerbations (Seemungal et al. AJRCCM 2001). The relationship between upper respiratory tract symptoms and HRV load at exacerbation presentation (ExP) and during recovery has not been described in naturally-occurring exacerbations. We quantified changes in airway HRV load at ExP and during the recovery period, in patients reporting symptoms of a cold, sore throat, or both.MethodsPatients in the London COPD cohort recorded new or increased respiratory symptoms on daily diary cards. Exacerbations were defined as an increase in respiratory symptoms for two consecutive days, with at least one symptom being major (dyspnoea, sputum purulence or volume) and the other a major or minor (wheeze, cold, sore throat, cough). Reverse-transcription quantitative PCR was used to detect and quantify HRV in 106 sputum samples collected at ExP (n = 38) and days 3 (n = 16), 7 (n = 27), 14 (n = 16), 35 (n = 6) and 56 (n = 3) following.ResultsHRV load decreased significantly from ExP to Day 3 in samples associated with either cold symptoms (p < 0.001) or sore throat (p = 0.049) but not in those associated with both symptoms (Figure 1). At Day 3 the HRV load in samples with both symptoms (n = 5) was significantly higher than in those with cold symptoms only (n = 9) (104.22(3.94-4.88) vs 100.55(0-1.98) pfu/ml; p = 0.002) but not for those with a sore throat only (n = 2) (100.89(0-0.89) pfu/ml; p = 0.095). At Day 7, the median (IQR) HRV load in samples with both symptoms (n = 4) (104.48(1.85-7.28) pfu/ml) was significantly higher than in those with cold symptoms only (n = 19) (100(0-2.74) pfu/ml; p = 0.018) or a sore throat only (n = 4) (100(0-0) pfu/ml; p = 0.029). There was no significant difference at subsequent time-points.ConclusionPatients reporting both cold symptoms and a sore throat as part of a COPD exacerbation had higher HRV loads than those with just one symptom until after Day 7 post-exacerbation. In patients with both symptoms, the HRV load remained higher for a longer period of time than in patients with only one symptom, which may suggest longer recovery times for more symptomatic patients. These results may inform the timing of administration of antiviral therapies at COPD exacerbation.[Figure]
Subject
This website uses cookies to ensure you get the best experience on our website.